|Table of Contents|

Clinical efficacy of ixazomib in the treatment of relapse/refractory multiple myeloma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 04
Page:
679-682
Research Field:
Publishing date:

Info

Title:
Clinical efficacy of ixazomib in the treatment of relapse/refractory multiple myeloma
Author(s):
YANG Ying; LIU Zhuogang; HU Rong
Department of Hematology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110022,China.
Keywords:
relapse/refractory multiple myeloma; ixazomib; efficacy; adverse reaction
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2021.04.030
Abstract:
Objective：To evaluate the efficacy and safety of a novel oral proteasome inhibitor,ixazomib,in the treatment of relapsed/refractory multiple myeloma.Methods:Patients with relapsed/refractory multiple myeloma treated with ixazomib-based chemotherapy regimens for at least 2 cycles at the department of hematology in Shengjing Hospital of China Medical University from 1 January 2018 to 31 August 2019 were selected.Overall response rate (ORR) was evaluated,including complete response (CR),very good partial response (VGPR),and partial response (PR).Adverse reactions also were observed.Results:27 patients were enrolled and ORR was 63.0%.2 patients achieved in CR.4 patients achieved in VGPR.11 patients achieved in PR,and median response time was 54 days.The common adverse reaction of ixazomib was gastrointestinal tract reaction,which did not lead to discontinuation of treatment.The peripheral neuropathy was not worsened during the treatment.Conclusion:In this single-center retrospective study,ixazomib showed good efficacy and safety in patients with relapse and refractory multiple myeloma.

References:

［1］ SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2017.CA［J］.Cancer J Clin,2017,67(1):7-30.
［2］ AVET-LOISEAU H,LELEU X,ROUSSEL M,et al.Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)［J］.J Clin Oncol,2010,28(30):4630-4634.
［3］ ROSINOL L,ORIOL A,RIOS R,et al.Bortezomib,lenalidomide,and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma［J］.Blood,2019,134(16):1337-1345.
［4］ TOUZEAU C,MOREAU P.Ixazomib in the management of relapsed multiple myeloma［J］.Future Oncol,2018,14(20):2013-2020.
［5］ KUMAR SK,BERDEJA JG,NIESVIZKY R,et al.Ixazomib,lenalidomide,and dexamethasone in patients with newly diagnosed multiple myeloma:Long-term follow-up including ixazomib maintenance［J］.Leukemia,2019,33(7):1736-1746.
［6］ RAJKUMAR SV,DIMOPOULOS MA,PALUMBO A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma［J］.Lancet Oncol,2014,15(12):e538-548.
［7］ LAUBACH J,GARDERET L,MAHINDRA A,et al.Management of relapsed multiple myeloma:Recommendations of the International Myeloma Working Group［J］.Leukemia,2016,30(5):1005-1017.
［8］ KUMAR S,PAIVA B,ANDERSON KC,et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma［J］.Lancet Oncol,2016,17(8):e328-e346.
［9］ FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Cancer incidence and mortality patterns in Europe:Estimates for 40 countries and 25 major cancers in 2018［J］.Eur J Cancer,2018,103:356-387.
［10］ MOREAU P,SAN MIGUEL J,SONNEVELD P,et al.Multiple myeloma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2017,28(suppl_4):iv52-iv61.
［11］ PANARONI C,YEE AJ,RAJE NS.Myeloma and bone disease［J］.Curr Osteoporos Rep,2017,15(5):483-498.
［12］ AILAWADHI S,MIKHAEL JR,LAPLANT BR,et al.Pomalidomide-dexamethasone in refractory multiple myeloma:Long-term follow-up of a multi-cohort phase II clinical trial ［J］.Leukemia,2018,32(3):719-728.
［13］ SAN-MIGUEL JF,HUNGRIA VTM,YOON SS,et al.Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial):A randomised,placebo-controlled,phase 3 trial［J］.Lancet Haematol,2016,3(11):e506-e515.
［14］ JAKUBOWIAK A,OFFIDANI M,PEGOURIE B,et al.Randomized phase 2 study:Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM［J］.Blood,2016,127(23):2833-2840.
［15］ GUPTA N,HANLEY MJ,XIA C,et al.Clinical pharmacology of ixazomib:The first oral proteasome inhibitor［J］.Clin Pharmacokinet,2019,58(4):431-449.
［16］ KUPPERMAN E,LEE EC,CAO Y,et al.Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer［J］.Cancer Res,2010,70(5):1970-1980.
［17］ CLEMENS J,WELTI L,SCHAFER J,et al.Bortezomib,carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions［J］.Oncol Lett,2017,14(3):3185-3192.
［18］ CHIM CS,KUMAR SK,ORLOWSKI RZ,et al.Management of relapsed and refractory multiple myeloma:novel agents,antibodies,immunotherapies and beyond［J］.Leukemia,2018,32(2):252-262.
［19］ AVET-LOISEAU H,BAHLIS NJ,CHNG WJ,et al.Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients［J］.Blood,2017,130(24):2610-2618.
［20］ GUPTA N,YANG H,HANLEY MJ,et al.Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma:Clinical and model-based analyses［J］.Target Oncol,2017,12(5):643-654.
［21］ MATEOS MV,MASSZI T,GRZASKO N,et al.Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1［J］.Haematologica,2017,102(10):1767-1775.
［22］ KUMAR SK,BERDEJA JG,NIESVIZKY R,et al.Safety and tolerability of ixazomib,an oral proteasome inhibitor,in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma:An open-label phase 1/2 study［J］.Lancet Oncol,2014,15(13):1503-1512.
［23］ BONNET A,MOREAU P.Safety of ixazomib for the treatment of multiple myeloma［J］.Expert Opin Drug Saf,2017,16(8):973-980.
［24］ ZAJACZKOWSKA R,KOCOT-KEPSKA M,LEPPERT W,et al.Mechanisms of chemotherapy-induced peripheral neuropathy ［J］.Int J Mol Sci,2019,20(6):E1451.
［25］ RICHARDSON PG,HOFMEISTER CC,ROSENBAUM CA,et al.Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma ［J］.Br J Haematol,2018,182(2):231-244.

Memo

Memo:
辽宁省教育厅项目（编号：JC2019011）
Last Update: 1900-01-01